Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Common Equity (2020 - 2023)

Historic Common Equity for Cullinan Therapeutics (CGEM) over the last 4 years, with Q3 2023 value amounting to $468.8 million.

  • Cullinan Therapeutics' Common Equity fell 2001.46% to $468.8 million in Q3 2023 from the same period last year, while for Sep 2023 it was $468.8 million, marking a year-over-year decrease of 2001.46%. This contributed to the annual value of $535.0 million for FY2022, which is 2577.85% up from last year.
  • As of Q3 2023, Cullinan Therapeutics' Common Equity stood at $468.8 million, which was down 2001.46% from $499.6 million recorded in Q2 2023.
  • Cullinan Therapeutics' 5-year Common Equity high stood at $604.6 million for Q2 2022, and its period low was $200.3 million during Q4 2020.
  • Moreover, its 4-year median value for Common Equity was $469.3 million (2021), whereas its average is $466.6 million.
  • Per our database at Business Quant, Cullinan Therapeutics' Common Equity soared by 11235.36% in 2021 and then tumbled by 2001.46% in 2023.
  • Cullinan Therapeutics' Common Equity (Quarter) stood at $200.3 million in 2020, then surged by 112.35% to $425.4 million in 2021, then increased by 25.78% to $535.0 million in 2022, then fell by 12.38% to $468.8 million in 2023.
  • Its last three reported values are $468.8 million in Q3 2023, $499.6 million for Q2 2023, and $485.6 million during Q1 2023.